Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.71 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653177 | 1.00 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL23979390 | 0.93 | CRBN (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL3654727 | 0.91 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL3653462 | 0.88 | CRBN (0.74) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL19954315 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL19954319 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL30892106 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL3651039 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL21464374 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL3650600 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2025-05-29 | — | — | US | disclosed |
| CN-118475567-A | Heterocyclic derivative, composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | AR, BCKDK, CYP11B2 | CRBN 2599/4885DDB1 3670/4885TNF 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.